PVLA

Palvella Therapeutics Stock Analysis

AI Rating

Good
  • Quality8/10
  • Growth↓ 4/10
  • Value↑ 7/10
Palvella Therapeutics sales and earnings growth
PVLA Growth
Neutral
  • Revenue Y/Y↑ 99.87%
  • EPS Y/Y↓ -112.89%
  • FCF Y/Y↓ -250.60%
Palvella Therapeutics gross and profit margin trends
PVLA Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 66162.30%
  • ROIC 5Y↑ -5.36%
Palvella Therapeutics net debt vs free cash flow
PVLA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -3.9

Palvella Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗